T 25
Generic Name: erlotinib
Pill imprint T 25 has been identified as Tarceva 25 mg.
Tarceva is used in the treatment of non-small cell lung cancer; pancreatic cancer; renal cell carcinoma and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy.
Tarceva 25 mg is not subject to the Controlled Substances Act.
See also related documents.
Tarceva Images
- Generic Name:
- erlotinib
- Imprint:
-
T 25
- Strength:
- 25 mg
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Inactive Ingredients:
- lactose monohydrate
hypromellose
hydroxypropyl cellulose
magnesium stearate
microcrystalline cellulose
sodium starch glycolate
sodium lauryl sulfate
titanium dioxide
FD&C Yellow No. 6
- Drug Class:
- EGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Genentech
- National Drug Code (NDC):
- 50242-0062
| NDC Code | Manufacturer / Repackager |
|---|---|
| 54868-5290 | Physicians Total Care Inc (repackager) |
Note: Inactive ingredients may vary.


